Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

计划入组 338 人 · 首次发布于 2022 年 1 月 25 日

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

计划入组 86 人 · 首次发布于 2025 年 9 月 10 日

Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

计划入组 90 人 · 首次发布于 2019 年 8 月 20 日

HER2+ Breast Cancer(Diakonos)

CLX-001

oncology program (HER2+ breast cancer)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

Gilead's Trodelvy Fails Primary Endpoint in First-Line HR+/HER2- Metastatic Breast Cancer Trial

NGS and Targeted Therapies Improve Survival in HR+/HER2- Breast Cancer

Puma Biotechnology Initiates Phase II Trial of Alisertib for HR+/HER2- Metastatic Breast Cancer